Paradigm raises AU$66M to fund pivotal trials for Zilosul for pain associated with knee osteoarthritis Aug. 16, 2022 By Tamra Sami Paradigm Biopharmaceuticals Ltd. announced a AU$66 million (US$46.39 million) capital raise to fund its phase III pivotal trial for injectable Zilosul (pentosan polysulfate) to treat osteoarthritis of the knee.Read More
